98results about How to "Increase bone mass" patented technology

Compositions and methods are provided for modulating the growth, development and repair of bone, cartilage or other connective tissue. Devices and stimulus waveforms are provided to differentially modulate the behavior of osteoblasts, chondrocytes and other connective tissue cells to promote proliferation, differentiation, matrix formation or mineralization for in vitro or in vivo applications. Continuous-mode and pulse-burst-mode stimulation of cells with charge-balanced signals may be used. Bone, cartilage and other connective tissue growth is stimulated in part by nitric oxide release through electrical stimulation and may be modulated through co-administration of NO donors and NO synthase inhibitors. Bone, cartilage and other connective tissue growth is stimulated in part by release of BMP-2 and BMP-7 in response to electrical stimulation to promote differentiation of cells. The methods and devices described are useful in promoting repair of bone fractures, cartilage and connective tissue repair as well as for engineering tissue for transplantation.

The present invention is based on that local administration of strontium ions in bone tissue has been found to improve the bone formation and bone mass upon implantation of a bone tissue implant in said bone tissue.

In particular, the invention relates to a bone tissue implant having an implant surface covered by an oxide layer comprising strontium ions and a method for the manufacture thereof.

A blasting powder comprising strontium ions, a method for locally increasing bone formation, and the use of strontium ions or a salt thereof for manufacturing a pharmaceutical composition for locally increasing bone formation are also provided by the present invention.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

The present invention provides methods for (i) reducing loss of bone mass or bone density, (ii) increasing bone mass or bone density, (iii) maintaining bone mass or bone density, and/or (iv) reducing loss of calcium from bone, comprising: administering to a subject a therapeutically effective amount of an NFAT agonist. The method could be used for treating, preventing or delaying a bone condition. The invention further provides a method for promoting healing of bone fractures or bone defects comprising: administering to a subject a therapeutically effective amount of an NFAT agonist. Compositions comprising NFAT agonists can also be used for the in vitro or in vivo generation of bone tissue. The invention also provides screening methods for agents which promotes, maintains, or reduces the loss of, bone mass, and the use of such agents for therapeutic purposes.

The invention as disclosed provides a method to increase bone mass without compromising bone strength or quality, through the administration to a host of a compound that binds to the estrogen or androgen receptor without causing hormonal transcriptional activation.

The invention relates to a minimally invasive bone fetcher. The minimally invasive bone fetcher comprises a sleeve, a connecting rod arranged in the sleeve in a penetrating mode and an abrasive drilling bit connected to the front end of the connecting rod. A water inlet channel and a discharge channel are formed in the sleeve. The sleeve is provided with a water inlet communicated with the water inlet channel and a discharge port communicated with the discharge channel. The discharge port is provided with a bone fragment collection container connected with a negative pressure suction device. The head end of the bone fetcher is small, a bone substance is abraded into bone fragments to be taken out through a minute skin incision and a minute bone window, then a minimally invasive bone fetching operation is rapidly completed, the risk of injuring the lateral femoral cutaneous nerve is greatly lowered, pain in the bone fetching area is alleviated, the occurrence rate of factures or ventral hernia is lowered, and the postoperative infection rate of the bone substance supply area is greatly decreased as well. The minimally invasive bone fetcher is easy to operate, saves labor and valuable operation time and brings great convenience to the bone fetching operation.

This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D₃. This compound is characterized by high bone calcium mobilization activity demonstrating preferential activity on bone. This results in a novel therapeutic agent for the treatment and prophylaxis of diseases where bone formation is desired, particularly osteoporosis. This compound also increases both breaking strength and crushing strength of bones evidencing use in conjunction with bone replacement surgery such as hip and knee replacements, as well as use by normal subjects when high bone mass is desired.

The invention relates to a preparation method of a porous titanium/hydroxyapatite composite material, and belongs to the technical field of biomedical material preparation. According to the method, metal pure titanium powder and hydroxyapatite ceramic powder are uniformly mixed; after the materials are uniformly mixed, the mixture is mixed with ammonium hydrogen carbonate to obtain mixed powder; the mixed powder is mechanically pressed into blocky pressed green compacts; then, the blocky pressed green compacts are put into a discharging plasma sintering furnace to be sintered in a gradient heating mode; demolding is performed, and the titanium/hydroxyapatite composite material is obtained. The porous titanium/hydroxyapatite composite material obtained through preparation has the characteristics that the elasticity modulus is low; the pore parameters are controllable; the physical adaptability is good, and the like. The porous titanium/hydroxyapatite composite material also has good bioactivity and bone combining capability. Along with the bone induction effect of the hydroxyapatite in the human body, the bone tissues are gradually induced to grow into the pores to realize the biological fixation, so that the bone integration effect is greatly improved. The material is particularly applicable to biomedical engineering with human body hard tissue defects, such as artificial joints, artificial bones and dental implants.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease reduce tumor burden in multiple myeloma and to block bone disease.

A composition for improving osteoporosis and increasing bone mineral density, a preparation method of the same and an application of the same in preparation of a health-caring product. The composition comprises an active ingredient and auxiliary materials and is characterized in that the active ingredient includes following components, by weight, 65-85 parts of a raw medicine in an extract of epimedium, 5-15 parts of glucosamine, 5-15 parts of chondroitin sulfate, 1.5-3.5 parts of collagen and a proper amount of vitamin D3; and the auxiliary materials include following components, by weight, 1.5-4.5 parts of an excipient and 0.2-1.5 parts of a lubricant. The composition is designed especially for middle-aged and elderly people and is strong in targeted performance. In the invention, the composition is prepared through integration of Chinese and western medicines, not only is traditional Chinese medicine guide theory inherited but also modern medicinal treatment methods are referenced. An experimental result proves that epimedium in the formula can increases the bone mineral density and the chondroitin sulfate, the glucosamine, the collagen and the vitamin D3 have an effect of improving the osteoporosis. The composition has excellent effects of increasing the bone mineral density and promoting absorption of calcium.

The present invention discloses a surface-drug-loading vertebroplasty dilatation balloon and a preparation method thereof. The surface-drug-loading vertebroplasty dilatation balloon comprises a balloon body, a drug-loading film is attached on surface of the balloon body, the drug-loading film is composed of at least two drug-loading coating layers, and the first drug-loading coating layer directlycontacting the balloon body is formed by electrospinning. The surface of the balloon body is provided with the drug-loading film, and the drug-loading film is composed of a plurality of the drug-loading coating layers, can be retained in body after the balloon is withdrawn, forms an outer shell enclosing bone cement, plays a function of effectively releasing the drugs at desired sites, improves function efficiency of the drugs, and also prevents the bone cement from detaching from positions. The vertebroplasty dilatation balloon has multiple functions, improves postoperative effects of percutaneous vertebroplasty and percutaneous kyphoplasty, and is especially suitable for treatments of osteoporosis and related compression fractures.

The invention discloses an extraction method and the application of an urogenic stem cell exosome. The extraction method comprises the following specific steps: firstly, collecting urine, then carrying out first-time centrifugation, and adding PBS into a first residual liquid obtained after supernatant is removed; carrying out second-time centrifugation, resuspending the second-time residual liquid obtained after the supernatant is removed through a primary culture medium to obtain urogenic stem cell suspension solution; secondly, carrying out multiplication culture on the urogenic stem cellsand passing down to the second to the sixth generation for later use; thirdly, changing the culture medium obtained in the second step, then continuously culturing, collecting and culturing supernatant, centrifuging, filtering and carrying out centrifugal concentration; adding an exosome extraction reagent for extracting to obtain a resuspension solution of the urogenic stem cells. The urogenic stem cell exosome extracted by the invention is proved by animal experiments to have the advantages of good therapeutic effects on senile osteoporosis, postmenopausal osteoporosis and disuse osteoporosis.

The invention discloses application of a compound traditional Chinese medicine to prevention and treatment of an osteoporosis disease, belonging to new application of the traditional Chinese medicine. The compound traditional Chinese medicine is prepared from the following Chinese medicinal herbs in percentage by weight: 15-35 percent of glossy privet fruit, 10-25 percent of Japanese thistle herbor root, 5-20 percent of largehead atractylodes rhizome, 5-20 percent of root of red-rooted salvia, 5-15 percent of coptis root, 5-15 percent of pseudo-ginseng root, 5-15 percent of eucommia and 5-15percent of fingered citron. As proved by an experiment, the compound traditional Chinese medicine has remarkable treatment effects on the prevention and treatment of primary osteoporosis, secondary osteoporosis, osteoporosis caused by hyperlipidaemia or an osteoporosis disease caused by glucose metabolism syndrome, definite clinical curative effect and no remarkable side effect according to observation.

The invention relates to a composition for preventing and/or treating osteoprosis, which comprises yak bone powder, active calcium, vitamin D3, D-Glucosamine Hydrochloride, isoflavones and an epimedium extract. The composition can prevent and/or treat the osteoprosis, has not toxic and side effects, does not induce other pathological changes or diseases.

The invention discloses an old-aged formula milk powder for preventing osteoporosis, and belongs to the technical field of blended milk powder and nutritional foods. The old-aged formula milk powder contains proteins, carbohydrates, lipids, vitamins, mineral substances and other nutrient substances, and also contains lactoferrin, hydrolyzed yolk powder, casein phosphopeptides and milk minerals. The formula milk powder well improves the dietary calcium sources, increases the absorption and utilization rate of calcium, keeps bone balancing, enhances the bone density, and has very good preventing and delaying effects of osteoporosis of the elderly.

The present invention relates to the discovery of novel receptors for the signaling of PTH and/or fragments of PTH, and the role of cPTH in bone development. The novel PTH receptors identified are selected from the group consisting of LRP5/6, TGFβRII, BMPRII (long form and short form), ActRIIA, and ActRIIB. Specifically, the present invention provides a novel screening tool for identifying compounds that improve bone mass by affecting certain pathways that promote or downregulate bone-forming activity. This promotion of bone-forming activity could provide for treatments for bone-loss or bone density disorders and/or kidney disease. The invention further encompasses the compounds, PTH ligands, and fragments of PTH ligands described herein; pharmaceutical compositions comprising the compounds, PTH ligands, or fragments of PTH ligand; and methods of increasing bone density using the compounds, PTH ligands, or fragments of PTH ligands.

The invention discloses a composition for improving the immunity. In the composition, a weight ratio of Ossotide to bone marrow peptide is 1-5:1; and a certain weight part of zinc lactate can be added. A preparation method for the composition comprises the following steps of: collecting fetal bovine marrow, washing and sterilizing the fetal bovine marrow, separating fat from the fetal bovine marrow, and separating protein from active substances; performing enzymolysis on the fetal bovine marrow twice, concentrating and drying the fetal bovine marrow to obtain the bone marrow peptide; collecting beef bones, washing and crushing the beef bones, and allowing the beef bones to enter a distillation retort to perform extraction; separating the fat from an extract, separating a supernatant, performing enzymolysis on the supernatant twice, and concentrating and drying the supernatant to obtain the Ossotide; and mixing the bone marrow peptide, the Ossotide and the zinc lactate uniformly in a proportion to obtain a formulation which is acceptable by a human body. The composition can improve the immunity of the human body, effectively resist the attack of diseases outside, and slow the speed of aging.

The invention discloses a Zn-Mg biphasic heterogeneous material and a preparation method thereof. The material is composed of Zn phases and Mg phases, the Zn phases are pure zinc or zinc alloys, the volume fraction of the Zn phases is 30%-99%, the grain size is smaller than or equal to 5 [mu]m, the Mg phases are pure magnesium or magnesium alloys, the Mg phases account for the remaining volume fraction, and the grain size is smaller than or equal to 10 [mu]m; the Mg phases are discontinuously distributed in the Zn phases, the size of the Mg phases is smaller than or equal to 50 [mu]m, and thedistance between every two adjacent Mg phases is larger than or equal to 50 nm; and the small Zn grains surround the large Mg grains. Compared with zinc alloy, the elastic modulus is obviously reduced, the stress shielding effect on bone tissue is reduced, and bone healing is facilitated. According to the material, Zn<2+> and Mg<2+> ions are separated out from the Zn phases and the Mg phases respectively, so that the concentration difference of the Zn phases and the Mg phases in surrounding bone tissues is realized, the osteogenesis promoting biological effect of the Zn phases and the Mg phases is maximized, the micro-roughness of the surfaces of the Mg phases and the Zn phases can be maintained in an in-vivo degradation process, and the material is more suitable for osteogenesis-related cells. The material can effectively avoid local swelling caused by the fact that release of a large amount of hydrogen exceeds the tissue removal capacity in a short time in the degradation process ofthe magnesium alloy.

The invention discloses a traditional Chinese medicine preparation for treating osteoporosis by means of tonifying qi and warming channels, and the traditional Chinese medicine preparation is prepared from the following crude medicines in proportion: 18-22 g of cornu cervi degelatinatum, 23-27 g of caulis lonicerae, 23-27 g of caulis spatholobi, 13-17 g of gentiana macrophylla, 13-17 g of saposhnikovia divaricata, 18-22 g of nidus vespae, 8-12 g of cinnamon, 18-22 g of ligusticum wallichii, 28-32 g of astragalus mongholicus, 18-22 g of rhizoma drynariae, 13-17 g of eucommia ulmoides, and 28-32 g of dipsacus asperoides. A method for preparing the preparation comprises the following steps of: placing the medicines in a medicine pot, adding water until the medicines are submerged, and soaking for 30-40 minutes at first; and then decocting to boil, keeping the boiling state for 20-40 minutes, taking off the medicine pot, and taking out the medicine solution in the medicine pot; and adding water until the medicines are submerged again, decocting to boil, keeping the boiling state for 20-40 minutes, taking off the medicine pot, taking out the medicine solution in the medicine pot, and combining the medicine solution obtained twice. The traditional Chinese medicine preparation disclosed by the invention has an obvious treatment effect on osteoporosis, and can be used for achieving the purpose of the invention..

The invention discloses composition with an effect of increasing bone mineral density as well as a preparation method and an application of the composition, and belongs to the technical field of traditional Chinese medicine. Effective ingredients of the composition are mainly prepared from raw materials in parts by weight as follows: 500-700 parts of deer bone, 260-300 parts of rhizoma polygonati, 180-240 parts of folium eucommiae, 200-300 parts of rhizoma polygonati odorati, 200-240 parts of rhizoma dioscoreae, 100-150 parts of lindera aggregata leaf, 60-100 parts of radix puerariae and 100-150 parts of semen sesami nigrum. In the composition, the deer bone serves as the monarch, the rhizoma polygonati, the folium eucommiae, the rhizoma polygonati odorati and the rhizoma dioscoreae serve as the minister, the lindera aggregata leaf, the radix puerariae and the semen sesami nigrum serve as assistant and the guide, and all the medicines have the effects of reinforcing the kidney, strengthening bone, invigorating the spleen, supplementing qi, promoting blood circulation and removing stasis after being jointly used. The modern medicine system proves that the composition has the advantages that the bone resorption level can be reduced after ovary removal, bone mass can be increased, bone mineral density can be increased effectively, and osteoporosis symptoms can be improved.

The invention discloses a pabular health tea electuary for preventing osteoporosis, which belongs to the field of nutritious foods and has good effect and rapid effect. The pabular health tea electuary is made from the raw materials such as astragalus mongholicus, fruit of Chinese wolfberry, barley grass, whey calcium, mycose and the like, has the functions of supporting body resistance, reinforcing qi, nourishing blood, nourishing yin and strengthening bone, and has the advantages of good effect and rapid effect.

The invention discloses a pharmaceutical composition for promoting bone healing after osteoportic fracture operations and application of the pharmaceutical composition. The pharmaceutical composition comprises statins and ketorolac tromethamine, wherein the statins are selected from one or more of simvastatin, lovastatin and atorvastatin. The pharmaceutical composition has the advantages of improving the bone mass of osteoporosis patients to a greater extent and accelerating the healing of osteoportic fracture to improve the mechanical property.